ES2061855T3 - Un metodo para la preparacion de un derivado de factor de crecimiento de fibroblastos basico humano o bovino. - Google Patents

Un metodo para la preparacion de un derivado de factor de crecimiento de fibroblastos basico humano o bovino.

Info

Publication number
ES2061855T3
ES2061855T3 ES89117112T ES89117112T ES2061855T3 ES 2061855 T3 ES2061855 T3 ES 2061855T3 ES 89117112 T ES89117112 T ES 89117112T ES 89117112 T ES89117112 T ES 89117112T ES 2061855 T3 ES2061855 T3 ES 2061855T3
Authority
ES
Spain
Prior art keywords
growth factor
derivatives
bfgf
preparation
fibroblast growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89117112T
Other languages
English (en)
Inventor
Laura Bergonzoni
Antonella Isacchi
Paolo Sarmientos
Gilles Cauet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Farmitalia Carlo Erba SRL
Carlo Erba SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmitalia Carlo Erba SRL, Carlo Erba SpA filed Critical Farmitalia Carlo Erba SRL
Application granted granted Critical
Publication of ES2061855T3 publication Critical patent/ES2061855T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Eye Examination Apparatus (AREA)

Abstract

EL PRESENTE INVENTO SE REFIERE A LA PRODUCCION, MEDIANTE TECNICA DE DNA RECOMBINANTE, DE DERIVADOS DEL FACTOR DEL CRECIMIENTO FIBROBLASTICO BASICO (BFGF). ESTOS DERIVADOS DEL (BFGF) PUEDEN ACTUAR COMO ANTAGONISTAS Y / O SUPERANTAGONISTAS DE LA MOLECULA DE TIPO SALVAJE EN EL PROCESO ANGIOGENICO.ESTOS DERIVADOS ASI COMO EL BFGF DE TIPO SALVAJE, PUEDEN PREPARARSE MEDIANTE EL USO DE CADENAS DE "E. COLI" QUE HAYAN SIDO TRANSFORMADAS CON PLASMIDOS QUE LLEVEN UNA CODIFICACION DE SECUENCIA NUCLEOTOIDE PARA BFGF HUMANO Y BOBINO Y SUS DERIVADOS.
ES89117112T 1988-09-16 1989-09-15 Un metodo para la preparacion de un derivado de factor de crecimiento de fibroblastos basico humano o bovino. Expired - Lifetime ES2061855T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB888821795A GB8821795D0 (en) 1988-09-16 1988-09-16 New derivatives of human/bovine basic fibroplast growth factor

Publications (1)

Publication Number Publication Date
ES2061855T3 true ES2061855T3 (es) 1994-12-16

Family

ID=10643728

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89117112T Expired - Lifetime ES2061855T3 (es) 1988-09-16 1989-09-15 Un metodo para la preparacion de un derivado de factor de crecimiento de fibroblastos basico humano o bovino.

Country Status (21)

Country Link
EP (2) EP0363675B1 (es)
JP (1) JP2888575B2 (es)
KR (1) KR900702027A (es)
CN (1) CN1041181A (es)
AT (1) ATE98693T1 (es)
AU (1) AU620925B2 (es)
CA (1) CA1340834C (es)
DE (1) DE68911461T2 (es)
DK (1) DK120290A (es)
ES (1) ES2061855T3 (es)
FI (1) FI902391A7 (es)
GB (1) GB8821795D0 (es)
HU (1) HUT53937A (es)
IL (1) IL91615A0 (es)
MY (1) MY104910A (es)
NO (1) NO902176L (es)
NZ (1) NZ230621A (es)
PT (1) PT91719B (es)
WO (1) WO1990002800A1 (es)
YU (1) YU179489A (es)
ZA (1) ZA897020B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143829A (en) * 1990-03-29 1992-09-01 California Biotechnology Inc. High level expression of basic fibroblast growth factor having a homogeneous n-terminus
US5478804A (en) * 1990-09-19 1995-12-26 The Salk Institute For Biological Studies Treatment of tumorigenic pathophysiological conditions with FGF-cytoxic conjugates
JP3135138B2 (ja) * 1990-12-19 2001-02-13 科研製薬株式会社 骨疾患治療剤
US6833354B1 (en) 1990-12-19 2004-12-21 Kaken Pharmaceutical Co., Ltd. Agent for the treatment of bone diseases
EP0505108B1 (en) * 1991-03-21 1995-10-18 The Procter & Gamble Company Compositions for regulating skin wrinkles comprising an Arg-Ser-Arg-Lys based peptide
JP3303211B2 (ja) * 1991-04-26 2002-07-15 武田薬品工業株式会社 ｂＦＧＦムテインおよびその製造法
TW275068B (es) * 1993-09-24 1996-05-01 American Cyanamid Co
AUPO247496A0 (en) 1996-09-23 1996-10-17 Resmed Limited Assisted ventilation to match patient respiratory need
US6214795B1 (en) * 1996-11-12 2001-04-10 Praecis Pharmaceuticals, Inc. Peptide compounds useful for modulating FGF receptor activity
US6274712B1 (en) 1997-12-23 2001-08-14 3-Dimensional Pharmaceuticals, Inc. Analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamute 89, aspartate 101 or leucine 137
FR2780416B1 (fr) * 1998-06-10 2002-12-20 Rhone Poulenc Nutrition Animal Procede industriel de production de proteines heterologues chez e. coli et souches utiles pour le procede
AU6634400A (en) 1999-08-13 2001-03-13 Chiron Corporation Dose of an angiogenic factor and method of administering to improve myocardial blood flow
WO2001046416A1 (en) * 1999-12-22 2001-06-28 3-Dimensional Pharmaceuticals, Inc. Analogs of human basic fibroblast growth factor
ES2305138T3 (es) 2000-11-27 2008-11-01 Dnavec Research Inc. Vector de paramixovirus que codifica factor 2 de crecimiento de fibroblastos (fgf2) y uso del mismo.
US8772460B2 (en) * 2011-12-16 2014-07-08 Wisconsin Alumni Research Foundation Thermostable FGF-2 mutant having enhanced stability
CN106957359B (zh) * 2016-08-31 2020-04-24 黄志锋 Fgf1突变体及其医药应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989000198A1 (en) * 1987-07-07 1989-01-12 Biotechnology Research Associates, J.V. Recombinant fibroblast growth factors
DK122687A (da) * 1986-03-14 1987-09-15 Takeda Chemical Industries Ltd Polypeptid, dna og anvendelse deraf
JPH01501840A (ja) * 1987-01-16 1989-06-29 アムジエン・インコーポレーテツド 繊維芽細胞成長因子の産生
JP2526965B2 (ja) * 1987-02-24 1996-08-21 武田薬品工業株式会社 ムテイン，ｄｎａおよびその用途
EP0326907A1 (en) * 1988-01-26 1989-08-09 Takeda Chemical Industries, Ltd. Polypeptide, DNA and its use

Also Published As

Publication number Publication date
MY104910A (en) 1994-06-30
PT91719B (pt) 1995-05-31
EP0363675B1 (en) 1993-12-15
AU620925B2 (en) 1992-02-27
JP2888575B2 (ja) 1999-05-10
YU179489A (en) 1991-10-31
CA1340834C (en) 1999-11-30
PT91719A (pt) 1990-03-30
GB8821795D0 (en) 1988-10-19
JPH03501855A (ja) 1991-04-25
DK120290A (da) 1990-07-16
NO902176D0 (no) 1990-05-15
EP0363675A1 (en) 1990-04-18
HU895573D0 (en) 1990-11-28
FI902391A0 (fi) 1990-05-14
NO902176L (no) 1990-07-13
CN1041181A (zh) 1990-04-11
DE68911461D1 (de) 1994-01-27
AU4317189A (en) 1990-04-02
EP0396664A1 (en) 1990-11-14
ATE98693T1 (de) 1994-01-15
ZA897020B (en) 1990-08-29
DE68911461T2 (de) 1994-05-19
WO1990002800A1 (en) 1990-03-22
NZ230621A (en) 1992-06-25
FI902391A7 (fi) 1990-05-14
DK120290D0 (da) 1990-05-15
IL91615A0 (en) 1990-04-29
HUT53937A (en) 1990-12-28
KR900702027A (ko) 1990-12-05

Similar Documents

Publication Publication Date Title
ES2169095T3 (es) Proteinas con actividad de factor viii, procedimiento para su produccion utilizando celulas modificadas por ingenieria genetica y composiciones farmaceuticas que los contienen.
DK120290A (da) Nye derivater af human/bovin basal fibroblastvaekstfaktor
DK323687A (da) Insulinprecursorer og fremgangsmaade til fremstilling deraf
ES474597A1 (es) Un procedimiento mejorado que permite obtner copoliamidas flexibles esencialmente lineales
KR870700099A (ko) 에리트로 포이에틴의 제조방법
MX9202129A (es) Proteina compuesta de dos cadenas unidas de disulfuro, proceso para su preparacion y composicion farmaceutica que la contiene.
DE3650751D1 (de) Antikörper gegen Saugetier-Interleukin-4 und Peptide verwendbar als Antigenen für deren Herstellung
DK213784A (da) Ikke-toxinogene vibrio choleraemutanter
ES2165843T3 (es) Moleculas de union al tgf-beta-1 similar al receptor, sustancialmente puras, y usos de las mismas.
ES2120964T3 (es) Peptidos osteogenicos.
DE3851002D1 (de) Lineare und zyklische Analoge von alpha-MSH-Fragmenten mit ausserordentlicher Wirkung.
DE3674406D1 (de) Einheit mit feder unter vorspannung.
ES2056105T3 (es) Di-t-butilfenoles sustituidos.
NO165804C (no) Veksthormon-frigjoerende peptider og anvendelse derav.
ES2156869T3 (es) Sintesis de colecciones diversas y utiles de oligonucleotidos.
AR038900A1 (es) Moleculas similares al interferon beta para el tratamiento del derrame cerebral
DK38889A (da) Onkogen-indkodet polypeptid med vaekstfaktoraktivitet
EP0712928A3 (es)
HUT44609A (en) Process for preparing new polypeptides
ES2044928T3 (es) Enzima alfa-amidante en terminal c y procedimiento para la produccion y el uso del mismo.
ES2052391T3 (es) Derivados de acido 5-aminosalicilico para la terapia de enfermedades inflamatorias cronicas del intestino.
DK45784D0 (da) Cyclisk hexapeptid,dets fremstilling og anvendelse
AR034853A1 (es) Secuencia de acido nucleico sintetico que codifica una alfa-galactosidasa, vector y celula que la comprenden, metodo para producir alfa-galactosidasa, metodo para prepararla, composicion farmaceutica que comprende dicha secuencia y su uso para preparar esta ultima
BR9911388A (pt) Imunógeno de somatostatina sintético para promoção de crescimento em animais de fazenda
DE58909261D1 (de) Ancrod-proteine, ihre herstellung und verwendung.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 363675

Country of ref document: ES